EGFRvIII/MMAE antibody drug conjugate (Abgenix)

N/A

Report date: 2023/07/13 14:38:10

Base Information

Drug NameEGFRvIII/MMAE antibody drug conjugate (Abgenix)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin inhibitorsAnti-EGFRvIII
TargetsTubulinEpidermal growth factor receptor variant III
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbgenix Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbgenix Incorporated
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A